Neuronetics Inc. (NASDAQ: STIM) recently reported its preliminary financial results for the fourth quarter of 2025, triggering a substantial 41.08% surge in its stock price during after-hours trading. This remarkable performance underscores the medical technology company's robust growth across its key business segments and its ability to generate positive operational cash flow. Investors are keenly observing the company's trajectory as it prepares to release its full fourth-quarter results, with optimism for continued positive momentum.
Neuronetics Achieves Significant Revenue Growth and Positive Cash Flow
In a significant announcement on February 11, 2026, medical technology innovator Neuronetics Inc. (NASDAQ: STIM) revealed preliminary financial results for the fourth quarter of 2025 that led to an impressive 41.08% increase in its stock price during after-hours trading, reaching $2.06 per share. The company reported a total revenue of $41.8 million for the quarter, marking a 23% rise on an adjusted pro forma basis and an astounding 86% increase compared to the fourth quarter of 2024. This growth was fueled by strong performances across its two primary segments.
Revenue generated from the NeuroStar system, which is recognized as the first transcranial magnetic stimulation (TMS) device to receive clearance from the Food and Drug Administration (FDA), climbed to $18.3 million, reflecting a 9% pro forma growth. Concurrently, the company's clinic segment experienced a significant boost, with revenue reaching $23.5 million, an increase of 37% on a pro forma basis.
Neuronetics also highlighted its operational achievements, noting the shipment of 49 NeuroStar Advanced Therapy systems during the quarter. Furthermore, the company successfully generated a positive operating cash flow of $0.9 million, aligning perfectly with its previously communicated guidance. These figures collectively showcase Neuronetics' strong financial health and operational efficiency.
For the entire fiscal year 2025, Neuronetics reported an aggregate revenue of $149.2 million, demonstrating a 15% increase on an adjusted pro forma basis. The year concluded with the company possessing a solid financial foundation, including $34.1 million in total cash and cash equivalents.
Keith Sullivan, President and CEO of Neuronetics, expressed satisfaction with the results, stating, "We translated this strong revenue performance into positive operating cash flow during the quarter." The company, headquartered in Pennsylvania, is set to unveil its complete fourth-quarter results on March 17, providing a more detailed overview of its financial standing and outlook.
From a market perspective, Neuronetics currently holds a relative strength index (RSI) of 38.16 and a market capitalization of $99.99 million. Over the past year, the stock has experienced a 62.85% decline, with its 52-week trading range spanning from $1.25 to $5.91. Despite closing at $1.46 on Tuesday, down 2.01%, the after-hours surge positions the stock significantly above its 52-week low. Investors are closely monitoring the stock's performance, as its current valuation suggests potential for recovery, although clear confirmation would be needed before substantial investment actions.
The impressive fourth-quarter preliminary results from Neuronetics highlight the growing potential and acceptance of advanced medical technologies in addressing complex health issues. The company's focus on innovative solutions like the NeuroStar system, coupled with its robust financial management, suggests a promising future. This growth not only benefits Neuronetics but also offers hope for patients seeking effective treatments for conditions that were once challenging to manage. The medical technology sector continues to be a fertile ground for investment and innovation, and Neuronetics' recent performance serves as a testament to this dynamic environment.